Senti Biosciences Holdings, Inc.

Senti Biosciences Holdings, Inc., operating as Senti Bio, is a clinical-stage biotechnology company headquartered in South San Francisco, California. Its mission is to develop a new generation of smarter medicines designed to outmaneuver complex diseases through novel and unprecedented approaches. [3, 4, 5, 10, 14, 17, 18, 25, 26, 32]

The company's core business revolves around its proprietary Gene Circuit platform, which engineers synthetic biology into next-generation cell and gene therapies. These Gene Circuits are created from novel DNA sequences to reprogram cells with biological logic, enabling them to sense inputs, compute decisions, and respond to their cellular environments. Senti Bio primarily applies this technology to develop off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapies for challenging liquid and solid tumor oncology indications. Its lead product candidate, SENTI-202, is a logic-gated CAR-NK cell therapy currently in a Phase 1 clinical trial for relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). SENTI-202 has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for treating relapsed or refractory hematologic malignancies, with a focus on AML. [3, 5, 10, 12, 14, 17, 28, 29, 33, 34, 36]

In recent corporate developments, Senti Biosciences completed a holding company reorganization on April 24, 2026, with Senti Biosciences Holdings, Inc. becoming the successor issuer, and its common stock continuing to trade on the Nasdaq Capital Market under the ticker symbol SNTI. [2, 23] The company also recently secured up to $40 million in senior secured convertible notes financing with an affiliate of Celadon Partners. [19, 23] Preliminary data from the SENTI-202 Phase 1 trial in relapsed/refractory AML has shown a 50% overall response rate and a 39% complete remission rate. [2] The leadership team includes Co-Founder and CEO Dr. Tim Lu, Chief Financial Officer Jay Cross, and President, Head of Research & Development and Chief Medical Officer Dr. Kanya Rajangam. [3, 5, 11, 12, 22]